Compare ASTRAZENECA PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PANACEA BIOTECH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PANACEA BIOTECH ASTRAZENECA PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 115.3 9.5 1,214.8% View Chart
P/BV x 33.7 3.7 912.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PANACEA BIOTECH
Mar-19
ASTRAZENECA PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,278354 361.4%   
Low Rs883138 638.6%   
Sales per share (Unadj.) Rs228.474.6 306.3%  
Earnings per share (Unadj.) Rs10.46.7 155.2%  
Cash flow per share (Unadj.) Rs16.315.5 104.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.857.2 172.7%  
Shares outstanding (eoy) m25.0061.25 40.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.3 143.4%   
Avg P/E ratio x104.236.8 283.1%  
P/CF ratio (eoy) x66.415.9 418.7%  
Price / Book Value ratio x10.94.3 254.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00815,061 179.3%   
No. of employees `0001.42.3 58.6%   
Total wages/salary Rs m1,5351,471 104.4%   
Avg. sales/employee Rs Th4,210.91,973.6 213.4%   
Avg. wages/employee Rs Th1,132.2635.6 178.1%   
Avg. net profit/employee Rs Th191.1176.8 108.1%   
INCOME DATA
Net Sales Rs m5,7104,567 125.0%  
Other income Rs m12345 273.4%   
Total revenues Rs m5,8334,612 126.5%   
Gross profit Rs m4632,030 22.8%  
Depreciation Rs m147540 27.3%   
Interest Rs m01,048 0.0%   
Profit before tax Rs m438486 90.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17977 232.0%   
Profit after tax Rs m259409 63.3%  
Gross profit margin %8.144.4 18.2%  
Effective tax rate %40.815.9 257.6%   
Net profit margin %4.59.0 50.7%  
BALANCE SHEET DATA
Current assets Rs m3,2092,415 132.9%   
Current liabilities Rs m2,0709,077 22.8%   
Net working cap to sales %20.0-145.9 -13.7%  
Current ratio x1.60.3 583.0%  
Inventory Days Days7265 111.1%  
Debtors Days Days3571 49.2%  
Net fixed assets Rs m7908,333 9.5%   
Share capital Rs m5061 81.6%   
"Free" reserves Rs m2,4193,443 70.3%   
Net worth Rs m2,4693,504 70.5%   
Long term debt Rs m0461 0.0%   
Total assets Rs m4,60513,755 33.5%  
Interest coverage xNM1.5-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.3 373.4%   
Return on assets %5.610.6 53.1%  
Return on equity %10.511.7 89.9%  
Return on capital %17.738.7 45.8%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m3001,203 24.9%   
Fx outflow Rs m2,015467 431.8%   
Net fx Rs m-1,715736 -232.9%   
CASH FLOW
From Operations Rs m881,049 8.4%  
From Investments Rs m-94-54 175.0%  
From Financial Activity Rs mNA-1,011 0.0%  
Net Cashflow Rs m-6-20 28.9%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 15.7 1.3 1,207.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   12,856 10,259 125.3%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS